目的观察基质金属蛋白酶-9(MM P-9)和基质金属蛋白酶组织抑制剂-1(T IM P-1)在子宫内膜异位症(EM s)患者子宫内膜中的表达,并探讨其在EM s发病机制中的作用。方法利用免疫组化法检测MM P-9和T IM P-1在35例EM s患者(观察组,其中未孕16...目的观察基质金属蛋白酶-9(MM P-9)和基质金属蛋白酶组织抑制剂-1(T IM P-1)在子宫内膜异位症(EM s)患者子宫内膜中的表达,并探讨其在EM s发病机制中的作用。方法利用免疫组化法检测MM P-9和T IM P-1在35例EM s患者(观察组,其中未孕16例、已孕19例)异位内膜及在位内膜组织和35例正常人(对照组)子宫内膜中的表达。结果①MM P-9在观察组异位内膜中的表达高于在位内膜和对照组(P均<0.05),在位内膜中的表达高于对照组(P均<0.05);②T IM P-1、MM P-9/T IM P-1在观察组异位内膜中的表达低于在位内膜和对照组(P均<0.05);观察组未孕与已孕患者MM P-9和T IM P-1表达以及MM P-9/T IM P-1均无统计学差异(P均>0.05)。结论MM P-9高表达以及MM P-9/T IM P-1的比例失调,使子宫内膜更具侵袭性,在EM s的发生、发展中起重要作用。展开更多
Objective To investigate the regulatory effect of multifactor on the matrix metalloproteinases-9 （MMP-9） and the tissue inhibitor of metalloproteinase-1 （TIMP-1） in endometrial stromal cells. Methods The endometri...Objective To investigate the regulatory effect of multifactor on the matrix metalloproteinases-9 （MMP-9） and the tissue inhibitor of metalloproteinase-1 （TIMP-1） in endometrial stromal cells. Methods The endometrial stromal cells separated from the proliferative endometrial tissues were incubated with medium alone, 17-β estradiol （E2,10^-8 mol/L）, medroxyprogesterone acetate （MPA, 10^-6 mol/L）, E2（10^-8 mol/L）＋MPA （10^-6 mol/L）, E2 （10^-8 mol/L）＋MPA （10^-6 mol/L）＋RU486 （10^-5 mol/L） or HB-EGF （10 ng/ml） for 48 h respectively. The expressions of MMP-9 and TIMP-1 were detected by in situ hybridization, immunocytochemistry, reverse transcriptase-polymerase chain reaction （RT-PCR） and Western blotting. Results Compared with control group [mRNA, 0. 729 ± 0. 090 （MMP-9） and 1.056± 0.154 （TIMP-1）; protein, 0.545 ±0.086 （MMP-9） and 0.745 ±0.154 （TIMP-1）], expressions of MMP-9 and TIMP-1 in E2 alone, progestin alone or E2 combined with progestin group were respectively：mRNA, 0.413 ± 0.069, 0.402 ± 0.073 and 0.407 ± 0.039; 0.487 ± 0.093, 0.503 ± 0.093 and 0.468 ± 0.075：protein, 0.294 ± 0.076, 0.331 ±0.064 and 0.265 ±0.049; 0.425 ±0.085, 0.397 ±0.065 and 0.435 ± 0.099. RU486 weakened the expression level of down-regulation, while HB-EGF elevated the level of MMP-9 and TIMP-1 after 48 h treatment （mRNA, 0.955 ± 0.068 and 1.396 ± 0.238; protein, 0. 780 ± 0.109 and 0.985 ± 0.165）. Conclusions 1） Both E2 and progestin can down-regulate the expressions of MMP-9 and TIMP-1 in endometrial stromal cells, but RU486 can inhibit the effect. 2） HB-EGF can elevate the level of MMP-9 and TIMP-1. 3） E2, progestin and HB-EGF have effect on the ratio of MM-P/TIMP-1.展开更多
文摘目的观察基质金属蛋白酶-9(MM P-9)和基质金属蛋白酶组织抑制剂-1(T IM P-1)在子宫内膜异位症(EM s)患者子宫内膜中的表达,并探讨其在EM s发病机制中的作用。方法利用免疫组化法检测MM P-9和T IM P-1在35例EM s患者(观察组,其中未孕16例、已孕19例)异位内膜及在位内膜组织和35例正常人(对照组)子宫内膜中的表达。结果①MM P-9在观察组异位内膜中的表达高于在位内膜和对照组(P均<0.05),在位内膜中的表达高于对照组(P均<0.05);②T IM P-1、MM P-9/T IM P-1在观察组异位内膜中的表达低于在位内膜和对照组(P均<0.05);观察组未孕与已孕患者MM P-9和T IM P-1表达以及MM P-9/T IM P-1均无统计学差异(P均>0.05)。结论MM P-9高表达以及MM P-9/T IM P-1的比例失调,使子宫内膜更具侵袭性,在EM s的发生、发展中起重要作用。
文摘Objective To investigate the regulatory effect of multifactor on the matrix metalloproteinases-9 （MMP-9） and the tissue inhibitor of metalloproteinase-1 （TIMP-1） in endometrial stromal cells. Methods The endometrial stromal cells separated from the proliferative endometrial tissues were incubated with medium alone, 17-β estradiol （E2,10^-8 mol/L）, medroxyprogesterone acetate （MPA, 10^-6 mol/L）, E2（10^-8 mol/L）＋MPA （10^-6 mol/L）, E2 （10^-8 mol/L）＋MPA （10^-6 mol/L）＋RU486 （10^-5 mol/L） or HB-EGF （10 ng/ml） for 48 h respectively. The expressions of MMP-9 and TIMP-1 were detected by in situ hybridization, immunocytochemistry, reverse transcriptase-polymerase chain reaction （RT-PCR） and Western blotting. Results Compared with control group [mRNA, 0. 729 ± 0. 090 （MMP-9） and 1.056± 0.154 （TIMP-1）; protein, 0.545 ±0.086 （MMP-9） and 0.745 ±0.154 （TIMP-1）], expressions of MMP-9 and TIMP-1 in E2 alone, progestin alone or E2 combined with progestin group were respectively：mRNA, 0.413 ± 0.069, 0.402 ± 0.073 and 0.407 ± 0.039; 0.487 ± 0.093, 0.503 ± 0.093 and 0.468 ± 0.075：protein, 0.294 ± 0.076, 0.331 ±0.064 and 0.265 ±0.049; 0.425 ±0.085, 0.397 ±0.065 and 0.435 ± 0.099. RU486 weakened the expression level of down-regulation, while HB-EGF elevated the level of MMP-9 and TIMP-1 after 48 h treatment （mRNA, 0.955 ± 0.068 and 1.396 ± 0.238; protein, 0. 780 ± 0.109 and 0.985 ± 0.165）. Conclusions 1） Both E2 and progestin can down-regulate the expressions of MMP-9 and TIMP-1 in endometrial stromal cells, but RU486 can inhibit the effect. 2） HB-EGF can elevate the level of MMP-9 and TIMP-1. 3） E2, progestin and HB-EGF have effect on the ratio of MM-P/TIMP-1.
